The company is a well-known global chain of ophthalmology medical institutions and an IPO-listed medical institution (stock code: 300015, selected as a stock in the Shanghai and Shenzhen 300 Index in 2015). As of 2019, more than 300 specialized ophthalmology hospitals have been established in 30 provinces and cities in mainland China, covering more than 70% of the country's health insurance population and the annual number of outpatients exceeding 6.5 million people. Furthermore, there are more than 80 eye hospitals in the US, Europe, and Hong Kong, China. As a professional ophthalmology chain, the company is mainly engaged in the diagnosis and treatment of various ophthalmologic diseases, surgical services and medical optometry. Currently, the medical network has spread across mainland China, Hong Kong, Europe, the United States, and Southeast Asia, setting a strategic pattern for global development. As a professional ophthalmology chain medical institution, the company is mainly engaged in the diagnosis and treatment of various ophthalmologic diseases, surgical services and medical optometry accessories. Honors received include Aer Ophthalmology winning the “Top Ten Listed Companies Most Respected by Investors” in China, Aer Ophthalmology receiving the Best Value for Continued Investment Award, the Most Influential Listed Company Leader Award, the Gold Medal Director's Award, and Aer Ophthalmology's 2017 Best Shareholder Return Award for Listed Companies in China.
Listing Date： 10/30/2009